We studied the cefotaxime (CTX)-resistant (MIC≥32 μg/ml) clinical isolates of
E. coli and
K. pneumoniae in Teikyo University Hospital from 1990 to 1996. The incidence of CTX-resistant isolates was 0.4% (6/1, 282) in
E. coli and 0.6% (7/1, 044) in
K. pneumoniae, in 1990. In 1995, the incidence of CTX-resistance increased to 1.7% (50/2, 910) in
E. coli (p=0.0013) and 7.2% (144/1, 996) in
K. pneumoniae (p<0.0001).
These species have been detected in the stool (86 isolates), urine (59 isolates), sputum (15 isolates), pus (15 isolates), throat (10 isolates) and others (12 isolates) in 1995.
MIC
50 of ampicillin (ABPC), ABPC with clavlanic acid (CVA) 5μg/ml, piperacillin (PIPC), PIPC with CVA 5μg/ml, ceftazidime, CTX, ceftizoxime, cefpodoxime, cefepime, aztreonam, cefmetazole, latamoxef, and imipenem used against 33 isolates (11 isolates of
E. coli, 22 isolates of
K. pneumoniae), which were detected in 1996-1997, was >512μg/ml, 8μg/ml, >512μg/ml, 8μg/ml, 4μg/ml, >512μg/ml, 16μg/ml, >512μg/ml, 256μg/ml, 32μg/ml, 2μg/ml, 0.25μg/ml and 0.25μg/ml, respectively.
This susceptibility pattern were very similar to the Toho-1 type β-lactamases producing strains.
View full abstract